Aquestive Therapeutics Inc (NASDAQ: AQST) is 119.80% higher on its value in year-to-date trading and has touched a low of $1.55 and a high of $6.23 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AQST stock was last observed hovering at around $4.57 in the last trading session, with the day’s loss setting it -0.13%.
Currently trading at $4.44, the stock is -14.29% and -11.06% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.62 million and changing -2.84% at the moment leaves the stock 13.83% off its SMA200. AQST registered 179.25% gain for a year compared to 6-month gain of 42.77%. The firm has a 50-day simple moving average (SMA 50) of $4.9924 and a 200-day simple moving average (SMA200) of $3.9007.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -9.76% loss in the last 1 month and extending the period to 3 months gives it a 4.23%, and is -18.68% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.00% over the week and 7.18% over the month.
Aquestive Therapeutics Inc (AQST) has around 135 employees, a market worth around $393.31M and $58.90M in sales. Profit margin for the company is -59.75%. Distance from 52-week low is 186.45% and -28.73% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.54%).
with sales reaching $13.13M over the same period.The EPS is expected to shrink by -234.62% this year, but quarterly earnings will post 13.38% year-over-year. Quarterly sales are estimated to shrink -0.60% in year-over-year returns.
Aquestive Therapeutics Inc (AQST) Top Institutional Holders
149.0 institutions hold shares in Aquestive Therapeutics Inc (AQST), with institutional investors hold 55.19% of the company’s shares. The shares outstanding are 91.18M, and float is at 77.55M with Short Float at 13.08%. Institutions hold 52.43% of the Float.
The top institutional shareholder in the company is BRATTON CAPITAL MANAGEMENT, L.P. with over 9.81 million shares valued at $25.51 million. The investor’s holdings represent 13.3274% of the AQST Shares outstanding. As of 2024-06-30, the second largest holder is VR ADVISER, LLC with 5.56 million shares valued at $14.44 million to account for 7.5468 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 5.45 million shares representing 7.4099% and valued at over $14.18 million, while VANGUARD GROUP INC holds 5.743 of the shares totaling 4.23 million with a market value of $10.99 million.
Aquestive Therapeutics Inc (AQST) Insider Activity
The most recent transaction is an insider sale by Schobel Alexander Mark, the company’s Chief Innovation/Tech Officer. SEC filings show that Schobel Alexander Mark sold 50,000 shares of the company’s common stock on Mar 15 ’24 at a price of $6.00 per share for a total of $0.3 million. Following the sale, the insider now owns 0.98 million shares.
Aquestive Therapeutics Inc disclosed in a document filed with the SEC on Mar 08 ’24 that Schobel Alexander Mark (Chief Innovation/Tech Officer) sold a total of 25,000 shares of the company’s common stock. The trade occurred on Mar 08 ’24 and was made at $5.19 per share for $0.13 million. Following the transaction, the insider now directly holds 1.04 million shares of the AQST stock.
